Research programme: anti-cancer therapeutics - Amberstone Biosciences
Latest Information Update: 05 Jan 2022
At a glance
- Originator Amberstone Biosciences
- Class Antineoplastics; Bispecific antibodies; Cytokines; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours